Shares of Exelixis (EXEL -6.4%) are trading lower today following yesterday's post-session trading halt, despite receiving approval from both the FDA and the European Medicines Agency for cabozantinib, a treatment for a rare type of thyroid cancer. Part of the reason for the dip can possibly be attributed to the lack of information on the drug going into the decision, plus skittishness following an unexplained cancellation of the FDA's vote on cabozantinib's NDA earlier this month.
Shares of Exelixis (EXEL -6.4%) are trading lower today following yesterday's post-session...
From other sites
at CNBC.com (Dec 8, 2014)
at CNBC.com (Sep 29, 2014)
at CNBC.com (Sep 2, 2014)
at CNBC.com (Aug 6, 2014)
at CNBC.com (Jul 28, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs